Added to YB: 2026-01-08
Pitch date: 2026-01-02
NOVO-B.CO [neutral]
Novo Nordisk A/S
-25.56%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.0T
Pitch Price
DKK 322.56
Price Target
N/A
Dividend
4.98%
EV/EBITDA
7.41
P/E
10.21
EV/Sales
3.71
Sector
Pharmaceuticals
Category
growth
Show full summary:
Theodosian Capital | Stocks Update 2/1/2026 - Novo Nordisk A/S
NOVO-B.CO (updatE): FDA approved first daily oral GLP-1 Wegovy pill for weight management, launching Jan 2025. Awaiting EU approval to expand market. Stock +10% on news. Trades 14.0x 2027 consensus earnings, 3.7% yield - cheap for large pharma but execution critical.
Read full article (1 min)